BioSpace News Archive

Axovant Gene Therapies Ltd. (Nasdaq: AXGT) (“Axovant”) today announced that it has commenced an underwritten public offering of its common shares and pre-funded warrants to purchase its common shares.

ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market leader in automated cell processing tools and services in the cell and gene therapy field, today announced that on February 13, 2020, the Company received notice from Boyalife Asset Holding II, Inc

Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet patient needs, today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the New Drug Application (NDA) for HTX-011 by up to three months

REGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced that it will host a conference call on Wednesday, February 26, 2020,

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the fourth quarter and fiscal year 2019 after the close of trading on Wednesday, March 4, 2020

Ironwood Pharmaceuticals, Inc. will present a corporate update at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 9:30 a.m. Eastern Time at the Lotte New York Palace in New York.

Pulse Biosciences, Inc. (Nasdaq: PLSE), a novel bioelectric medicine company, today announced plans to participate in the upcoming Cowen Health Care Conference in Boston, Massachusetts.

Myomo, Inc. announced the closing of its previously announced underwritten public offering of 2,143,000 shares of common stock or common stock equivalents and 2,143,000 investor warrants to purchase one share of common stock at a combined offering price of $7.00.

An INRS team is developing a treatment combining fruit extracts and irradiation to prevent outbreaks of foodborne infections

Diasome Pharmaceuticals, Inc., a company developing hepatocyte directed vesicle (HDV) technology that can be added to any commercially available insulin to optimize treatment for people living with diabetes, today announced positive results from its Phase 2 OPTI-1 study of injectable hepatocyte directed vesicle (HDV) added to mealtime insulin in people with type 1 diabetes (T1D).